INTRODUCTION
The pharmacokinetics of SASP in rat as shown in preceding papers'-3) was similar to that in man4), with respect to absorption and metabolism, but the plasma clearance was far more rapid in the rat. In human studies, a high daily dose of SASP (4g) to healthy volunteers resulted in steady state concentrations of SASP in serum ranging from 4. 7 to 45pg/m15). Similar serum concentrations of SASP was also found in Japanese healthy volunteers 6) and in patients with ulcerative colitis) after repeated dosing. Information about pharmacokinetics in animals after multiple doses of SASP is scarce. Thus the present studies were designed to evaluate the distribution, metabolism and elimination of [3 H, 14CISASP after repeated daily administration to the rat. Separate enzyme induc tion studies were performed with unlabelled SASP.
MATERIALS AND METHODS

Materials
[14C] and [3H]SASP was prepared as described earlier) with 14C in the 5-aminosalicylic acid moiety and 3H in the phenyl ring in the sulfonamide moiety of SASP. The specific activity of C19CISASP thus obtained was 183MBq/mmol (4.94mCi/mmol). The radiochem ical purity judged by thin layer and liquid chromatography was >97%. The specific activity of [3HISASP was 2.87GBq/mmol (77.5mCi/mmol) and the radiochemical purity was >97% according to thin layer and liquid chromatography.
SASP was obtained from Pharmacia AB, Uppsala, Sweden and metabolites of SASP were synthesized in the department of Organic Chemistry, Pharmacia AB, Uppsala. Oth er chemicals used were of analytical grade obtained from different suppliers.
Animals and dosage
Male and female Sprague Dawley rats were purchased from Alab AB, Sollentuna, Sweden. The animals were 90-120 days old and weighed 230.412g. The rats were housed in temperature and humidity controlled rooms (17-22C and 31^-60% respectively) with 12 hours light-dark cycle for at least one week before the experiment. The animals were fed laboratory chow TWOS R32 Sodertalje, Sweden) ad libitum, and were starved over night before the last dose was given. Three animals were used in each group. The daily oral doses were 50mg/kg C3H, 14CISASP with 2 and 4MBq/kg of 14C and 3H respectively in a volume of 1ml. The drug was administered by gavage once daily during 2ldays. In the autoradiographic study the last dose contained to 334MBq/kg of 3H radioactivity and no 14C radioactivity. In another autoradiographic study pregnant rats gestational day 9
at the start of the experiment were administered 50mg/kg of unlabelled SASP orally for 10 days and thereafter an i. v. dose of either 14C or 3H labelled SASP (25MBq/kg or 35
MBq/kg respectively) was given.
In an enzyme induction study male Wistar rats were used. These animals were sup plied from Tokyo Laboratory Animals Co. Ltd., Japan. At the start of the experiment they were 4 weeks old. SASP was administered orally as a suspension in water at daily doses of 50 and 500mg/kg b.w., respectively. Phenobarbital-NA (analytical grade, Wako Pure Chemicals Co. Ltd., Japan)
was administered intraperitoneally at 25mg/kg b.w.
After 14 days of treatment half of the group including a control group were examined one day after the final dose. The other animals were examined one week after the end of the treatment.
Tissue distribution study by dissection
The rats were housed in individual metabolism cages for urine and faeces collection during 24 hours after the first, 7th, 14th and 21st dose. In one of these groups the urine and faeces collection continued for further 3 days after the last dose.
Blood was sampled from the orbital plexus under ether anaesthesia at time 0, 4, 8 and 24 hours after day and dose number 1, 7, 14 and 21. From each animal, blood samples were taken at 3 occasions during the period. Blood was collected by heart puncture under ether anaesthesia at 4, 8, 12, 24 and 96 hours after the last dose. The animals were then sacrificed and different tissues were dissected from the male rats. All gastrointestinal tissues were collected together with its content.
Three groups of male rats were sacrificed 4 hours after the dose on day 1, 7 and 14.
Blood and tissues were collected as described above.
The faeces was homogenized with methanol (3 times by weight). The homogenized samples as well as the urine and tissues were kept at -201C until analysed.
The blood was collected in heparinized tubes. One part of the blood was directly analy sed for radioactivity, the rest was centrifuged and the plasma was stored at -20C for analyses.
Whole body autoradiography
The technique of whole body autoradiography has earlier been described"). Briefly; the animals were killed by COL inhalation at the intended times. They were rapidly fro zen in hexan cooled on dry ice (-70C) and then mounted for sectioning in a gel of car boxymethyl cellulose (CMC The metabolites of SASP were determined by enzymatic hydrolysis of glucuronide and sulphate conjugates followed by reversed phase liquid chromatography on a C18 column using an aqueous metanolic eluent containing hexane sulphonic acid and triethylamine.
An UV-detector, and a fluorescence detector were coupled in series. The limits of deter mination were 1. 3, 3.4 and 3. 8pmole/l in plasma, urine and faeces respectively for SASP and for SASP metabolites between 3.3 to 21.9pmole/l. It was not possible to determine 5ASA due to interfering peaks from endogenous com pounds in the chromatograms obtained with this system.
Calculations and statistics
The measured radioactivity was referred to the wet weight of the tissues and was cal culated as equivalent concentrations (p M eq). The concentrations of radioactivity were also adjusted for the differences in the individual doses by normalizing the values to the same dose, 50mg/kg.
The arithmetic mean with standard error of the mean (SEM) was calculated for the groups. Statistical significance was evaluated by Student' t-test and analysis of variance.
RESULTS
Blood and plasma concentrations of 14C, 3H, SASP and metabolites
The peak concentrations of both radionuclides in plasma, found 8 hours after the ad ministration, were slightly increased, although not statistically significant, from dose 1 to (open symbols) and female rats (filled symbols) rats at 8 hrs (circles) and at 24 hours(triangles) after daily repeated oral doses of C3H, 14CISASP 50mg/kgx day. Mean ± SEM, n=3. dose 21 (Fig. 1 a, b) . The 14C concentrations were slightly higher in the males than in the females. The 3H level was more than two times higher in the female compared to that in the male rats. The concentration of radioactivity at 24 hours was unchanged during the treatment period. The blood concentration was lower than that in plasma . The ratio between the plasma and blood concentrations of 14C was about 2 at peak time (at 8 hours) in both male and female rats. The ratio was slightly decreased during the re peated administration, and after the 21st dose, the ratio was at peak time 1. 6 and 1. 3 in the male and female animals respectively. The ratio between plasma and blood concentra tion of 3H was about 1. 9 at peak time and was not changed during administration. The elimination rate from plasma was similar after repeated doses as after a single dose (Fig. 2 a, b) .
Unchanged SASP could not be detected in plasma by liquid chromatography. The metabolites that were quantified by HPLC were sulfapyridine(SP), N-acetylsulfa pyridine (AcSP), hydroxylated sulfapyridine (SPOH), N-acetyl-hydroxysulfapyridine (Ac SPOH) and 5-acetamidosalicylic acid (Ac5ASA). The same metabolites were found in similar proportions after single and repeated administration. There was a clear sex dif ference. The main metabolites in the male rats were in the order SP>AcSPOH>SPOH> AcSP. In female rats no hydroxylated SP-metabolites were found in plasma. The main metabolites were in the order SP>AcSP.
Urinary and faecal excretion of 14C, 3H, SASP and metabolites
No essential changes in the excretion of radioactivity were seen during the repeated administration (Fig. 3 , 4) . 14C was mainly excreted in the faeces while 3H was mainly excreted in the urine. The faecal excretion was lower in the females than in male, espe cially for 3H.
Unchanged SASP was not detected in urine from the female rats. In the male rats small amounts were detected in some of the animals, preferentially after repeated doses. In the faeces small amounts were detected in some samples from both male and female rats.
The metabolite pattern found in urine was not changed during the repeated administra Table   I a Tissue concentration of [14C] nmol eq/g during multiple daily oral dose of L14C , 3H ISASP 50mg/kg for 21 days to male rats, tion. However, there was a large sex difference.
In the males the amounts of excreted metabolites were in the order AcSPOH > SPOH > Ac5ASA > AcSP > SP while in female rats the amount of excreted metabolites were AcSP > Ac5ASA > SP > SPOH > AcSPOH. The metabolite pattern in faeces was not changed during the repeated administration.
Radioactivity in tissues
The concentrations of 14C and 3H in tissues at 4 hours after dose number 1, 7, 14, 21 in addition to 96 hours after the 21st dose are shown in Table la However, the 14C increased more than the increase of the plasma concentration for sever al tissues.
The highest concentration of 14C 4 hours after administration of the last dose was be sides the gastrointestinal tract, found in the kidneys, thyroid, plasma and in the liver, 10
13nmole eq/g. The highest increase of the ratio of the concentration tissue/plasma was seen in the thyroid followed by the thymus and the spleen ( Table Ia) . The highest con centration of 3H was besides the gastrointestinal tracts, found in the kidneys, liver and plasma, ranging between 61 and 106nmole eq/g. The ratio 3H/14C reflecting the relation between sulfapyridine and 5ASA metabolites, In (a) the uptake at 4 hours afte r21 days daily treatments, and in (b) the uptake at 4 hours after a single oral dose. Note a rather high concentration in the connective tissues, and within the testicles after 21 days of treatment (a).
Fig. 6 Autoradiograms
showing the distribution of L3H 1 labelled SASP in male rats after oral administration.
In (a) the distribution at 16 hours after 21 days daily treatments, and in (b) the distribution at the same time, but after just a single dose. Note a somewhat higher tissue concentration in (a). Fig. 7 Autoradiograms showing the distribution of 3H I labelled SASP in male rats 96 hours after oral administration.
In (a) after 21 days daily treatments, and in (b) after just a single dose. Note a faint of radioactivity in the intestines after repeated doses, but no radioactivity after a single dose (b ). was initially high in all tissues except the intestinal parts with its content. After repeated administration, the ratio decreased in all the tissues having the initial high ratio.
The 3H radioactivity was eliminated faster than the 14C activity and 96 hours after the last dose almost equivalent and very low concentrations of both radionuclides remained except for those in the gastrointestinal tract where the highest concentration was found in caecum.
In the autoradiographic study the rats had been administered [14C, 3HISASP for 20 days before the final dose which had a 100-fold higher specific activity of 3H. All studied tissues showed gradually decreasing 3H radioactivity with time after the last dose. The testicles however had its peak concentration at 16 hours. Only faint of radioactivity re mained in the liver, the kidney and within the gastrointestinal tract 96 hours after the last administration.
Beside the gastrointestinal tract , the highest distribution was found at4 hours after the final dose in the kidney cortex, the penis, the testicles, the epididymis, the liver, the connective tissues, the pituitary gland, and the lung (Fig. 5) . At 16 hours the highest uptakes were found in the kidney cortex, the liver and the connective tissues and at 96 hours in the kidney cortex and the liver (Fig. 6, 7 ).
Within the gastrointestinal tract relatively high radioactivity was seen in the stomach, the small intestines and the colon from 4 hours to 96 hours.
In the autoradiographic study with oral pretreatment of unlabelled SASP for 10 days, the pretreatment did not rise the radioactivity after an i.v. injection in fetal tissues com pared to after a single i.v. dose (Fig. 8 ) . A rise was seen in the placenta and the yolk sac for both labellings, but was most evident for the 3H-labelling.
Enzyme induction studies
The hepatic protein and enzyme concentrations obtained after 14 days of treatment with SASP or phenobarbital as a reference compound are presented in Table II . A comparison was made between livers from animals analysed one day after the final dose (treated) and values obtained from livers excised from rats which had a one week drug free period before examination (recovered).
The relative liver weights (% of body weight) in SASP treated animals were not signif icantly different from the control groups neither in treated or " recovered " groups , show ing that SASP does not induce hepatomegaly even at the higher dose of 500mg/kg b . w.
The hepatic cytochrome P-450 content showed a 2-fold increase in the phenobarbital-treat ed group although after withdrawing the drug the content decreased to around the con trol level. However, the SASP-treated groups did not differ significantly from the control.
In one " recovered " group receiving SASP (50mg/kg b.w.), a significant decrease in the cytochrome content was observed. However, the change was not dose-dependent, suggest ing that the change might be artefactual and of no biological significance. The phenobar bital-treated and SASP-treated groups (500mg/kg) showed slight increases in hepatic cytochrome b5. A slight decrease in the activities of aminopyrine demethylase and aniline hydroxylase was observed in the " recovered "SASP (50mg/kg) groups. In the phenobar bital-treated group the aminopyrine demethylase activity tended to increase while the ani line hydroxylase activity decreased slightly. FAOS, a hepatic peroxisomal enzyme, was slightly increased in the SASP-treated group, 500mg/kg.
DISCUSSION
The bioavailability of SASP is low, (about 9 % in the rat) and the half-life in plasma is short, (8 min) as previously shown'). Thus, the dose used in this study , (50mg/kg) which is somewhat higher than the therapeutic dose, gave no measurable levels of un changed SASP in plasma during the period of treatment. However, by using labelled SASP, with 14C in the 5ASA moiety and 3H in the sulfapyridine part, the drug together with its main metabolites could separately be followed.
It has previously been shown that after an oral dose of SASP to the rat , sulfapyridine metabolites were mainly present in plasma which in this study corresponds to the 3H radioactivity'). After repeated daily oral doses, the peak level of 3H in plasma slightly but not significantly increased in the male and female rat. The hepatic peroxisomal enzymes, FAOS, is considered to be the most sensitive bio chemical marker for peroxisome proliferation. The slight increase in the activity observed in the group treated with SASP (500mg/kg b.w.) and the slight dose dependency, were remarkably small compared to the results reported for other peroxisome proliferators.
The metabolism of sulfapyridine was different in male and female rats as previously has been shown 1-3). The main difference was a higher oxidative metabolic capacity in male rats resulting in more of hydroxylating sulfapyridine in male compared female rats.
A sex difference in metabolism is common in rats and might be linked to either sex hormones 20) or a higher content of cytochrome P-450 content of the liver microsomes in male compared to female rats 21). The hydroxylated sulfapyridine was further conjugated and rapidly excreted in urine or eliminated through the bile resulting in higher faecal excretion and lower plasma levels of tritium in male rats. Such sex differences were seen throughout this study.
The tissue distribution pattern was roughly the same when comparing single and re peated administration'). 
